Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niraparib and Dostarlimab in advanced NSCLC and MPM
NCT04940637Phase 2Unknown
- Sponsor
- University of Turin
- Start
- Dec 2020
- Primary completion
- Jun 2024
- Modality
- Immune Checkpoint Inhibitors, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of niraparib and dostarlimab in non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma (MPM), sponsored by University of Turin. Primary endpoint: Progression-Free Survival at 36 months. Status: unknown.
02
Drugs
niraparibdostarlimab
03
Conditions
non-small cell lung cancer (NSCLC)malignant pleural mesothelioma (MPM)
Beyond the preview
Go deeper on NCT04940637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04940637.